M6A methylation has been considered to be the most universal internal cotranscriptional modification in mRNA or long non-coding RNA (lncRNA) in eukaryotes since its discovery in 1974.[12] It mainly interacts with three classes of regulators: the m6A methyltransferases, known as writers; m6A-binding proteins, also called reader; and the demethylases, known as eraser.[13] Plenty of studies have demonstrated the crucial role of m6A RNA methylation regulators in physiological and pathological processes, especially in the occurrence and development of human cancers.[14–16]. The gene discussed is MBD2; the disease is cancer.